ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011
Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.
Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 85 citations in OpenAlex.
- Trial
- Trial
- Trial
- TRIB2 regulates the expression of miR‑33a‑5p through the ERK/c‑Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells.International journal of oncology · 2022Article
- Article
- Signaling pathways involved in chronic myeloid leukemia pathogenesis: The importance of targeting Musashi2-Numb signaling to eradicate leukemia stem cells.Iranian journal of basic medical sciences · 2019Review
- Novel AF1q/MLLT11 favorably affects imatinib resistance and cell survival in chronic myeloid leukemia.Cell death & disease · 2018Article
- Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.Molecular cancer · 2018Review
- [Comparative study of cytogenetic response evaluated by conventional banding analysis and fluorescence in situ hybridization in chronic myeloid leukemia patients during tyrosine kinase inhibitor treatment].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2017Article
- Article
- Article
- Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Article
- Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain.Oncotarget · 2016Article
- Article
- Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.Molecular cancer therapeutics · 2016Article
- [Effects of Sinopodophyllum hexundrum on apoptosis in K562 cells].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2016Article
- Review
- Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Chronic myeloid leukemia (CML) has been a model disease in the development of targeted therapies. After nearly 40 years of the recognition of the chromosomal abnormality that defines CML, specific therapy was developed, initially with imatinib mesylate, which has transformed our treatment algorithms and has changed the natural history of the disease. Today, most patients have the expectation of a favorable outcome when treated with standard-dose imatinib. However, a significant proportion of patients do not achieve the optimal desirable outcome. Effective salvage therapy followed the recognition of some of the most common mechanisms of resistance. More recently, the focus has turned to new areas of research and medical need, such as improving the front-line therapy to minimize the risk of resistance, to fight the most resistant mutant forms of BCR-ABL, and to eliminate minimal residual disease with the goal of achieving total elimination of the disease and treatment discontinuation. In this review, we analyze the current status of therapy of CML, and we discuss some of the most relevant clinical questions that we face today.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.